Modality
mAb
MOA
BETi
Target
CFTR
Pathway
NF-κB
BCCIPFParkinson's
Development Pipeline
Preclinical
~Nov 2021
→ ~Feb 2023
Phase 1
May 2023
→ Apr 2027
Phase 1Current
NCT06176315
1,031 pts·IPF
2023-05→2027-04·Active
1,031 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-10-116mo agoFast Track· Parkinson's
2027-04-211.1y awayInterim· IPF
Trial Timeline
Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2
P1
Active
Catalysts
Fast Track
2025-10-11 · 6mo ago
Parkinson's
Interim
2027-04-21 · 1.1y away
IPF
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06176315 | Phase 1 | IPF | Active | 1031 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-179 | Johnson & Johnson | Approved | KRASG12C | |
| Nidasacituzumab | Eli Lilly | Approved | CFTR | |
| LLY-1592 | Eli Lilly | NDA/BLA | FGFR | |
| Sovarapivir | AbbVie | Phase 2/3 | IL-13 | |
| Datoglumide | AbbVie | Approved | CFTR | |
| SNY-7254 | Sanofi | Phase 2 | CFTR | |
| SNY-5894 | Sanofi | Approved | CFTR | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| BII-1564 | Biogen | Phase 2 | PSMA | |
| Sovanaritide | Argenx | Phase 3 | TNFα |